Choice and Duration of Anticoagulation for Venous Thromboembolism.
Aroosa MalikNghi B HaGeoffery D BarnesPublished in: Journal of clinical medicine (2024)
Venous thromboembolism (VTE) is a prevalent medical condition with high morbidity, mortality, and associated costs. Anticoagulation remains the main treatment for VTE, though the decision on when, how, and for how long to administer anticoagulants is increasingly complex. This review highlights the different phases of VTE management, with special circumstances for consideration such as antiphospholipid syndrome, coronary artery disease, cancer-associated thrombus, COVID-19, and future anticoagulation options. Anticoagulation management will continue to be a complex decision, applying evidence-based medicine to individual patients with the hope of maximizing effectiveness while minimizing risks.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- coronary artery disease
- coronavirus disease
- cardiovascular events
- decision making
- sars cov
- randomized controlled trial
- systematic review
- healthcare
- atrial fibrillation
- percutaneous coronary intervention
- current status
- risk assessment
- cardiovascular disease
- coronary artery bypass grafting
- risk factors
- acute coronary syndrome
- climate change
- combination therapy
- left ventricular
- transcatheter aortic valve replacement
- respiratory syndrome coronavirus
- replacement therapy